CoChat

Landscape and selection of vaccine epitopes in SARS-CoV-2

Open access
Smith, Christof C., Olsen, Kelly S., Gentry, Kaylee M., Sambade, Maria, Beck, Wolfgang, Garness, Jason, Entwistle, Sarah, Willis, Caryn, Vensko, Steven, Woods, Allison, Fini, Misha, Carpenter, Brandon, Routh, Eric, Kodysh, Julia, O’Donnell, Timothy, Haber, Carsten, Heiss, Kirsten, Stadler, Volker, Garrison, Erik, Sandor, Adam M., Ting, Jenny P. Y., Weiss, Jared, Krajewski, Krzysztof, Grant, Oliver C., Woods, Robert J., Heise, Mark, Vincent, Benjamin G., Rubinsteyn, Alex · 2021 · Genome Medicine
Cited by 65

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Early in the pandemic, we designed a SARS-CoV-2 peptide vaccine containing epitope regions optimized for concurrent B cell, CD4 + T cell, and CD8 + T cell stimulation. The rationale for this design was to drive both humoral and cellular immunity with high specificity while avoiding undesired effects such as antibody-dependent enhancement (ADE). Methods: We explored the set of computationally predicted SARS-CoV-2 HLA-I and HLA-II ligands, examining protein source, concurrent human/murine coverage, and population coverage. Beyond MHC affinity, T cell vaccine candidates were further refined by predicted immunogenicity, sequence conservation, source protein abundance, and coverage of high frequency HLA alleles. B cell epitope regions were chosen from linear epitope mapping studies of convalescent patient serum, followed by filtering for surface accessibility, sequence conservation, spatial localization near functional domains of the spike glycoprotein, and avoidance of glycosylation sites. Results: From 58 initial candidates, three B cell epitope regions were identified. From 3730 (MHC-I) and 5045 (MHC-II) candidate ligands, 292 CD8 + and 284 CD4 + T cell epitopes were identified. By combining these B cell and T cell analyses, as well as a manufacturability heuristic, we proposed a set of 22 SARS-CoV-2 vaccine peptides for use in subsequent murine studies. We curated a dataset of ~ 1000 observed T cell epitopes from convalescent COVID-19 patients across eight studies, showing 8/15 recurrent epitope regions to overlap with at least one of our candidate peptides. Of the 22 candidate vaccine peptides, 16 (n = 10 T cell epitope optimized; n = 6 B cell epitope optimized) were manually selected to decrease their degree of sequence overlap and then synthesized. The immunogenicity of the synthesized vaccine peptides was validated using ELISpot and ELISA following murine vaccination. Strong T cell responses were observed in 7/10 T cell epitope optimized peptides following vaccination. Humoral responses were deficient, likely due to the unrestricted conformational space inhabited by linear vaccine peptides. Conclusions: Overall, we find our selection process and vaccine formulation to be appropriate for identifying T cell epitopes and eliciting T cell responses against those epitopes. Further studies are needed to optimize prediction and induction of B cell responses, as well as study the protective capacity of predicted T and B cell epitopes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-021-00910-1

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 65

Metadata

Authors
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W., Garness, J., Entwistle, S., Willis, C., Vensko, S., Woods, A., Fini, M., Carpenter, B., Routh, E., Kodysh, J., O’Donnell, T., Haber, C., Heiss, K., Stadler, V., Garrison, E., Sandor, A. M., Ting, J. P. Y., Weiss, J., Krajewski, K., Grant, O. C., Woods, R. J., Heise, M., Vincent, B. G., & Rubinsteyn, A.
Venue
Genome Medicine
Published
2021-06-14
Volume
13
Issue
1
Pages
101-101
ISSN
1756-994X (ISSN-L)
OpenAlex
W3167398245
Cited by
65
References
48
FWCI
3.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Landscape and selection of vaccine epitopes in SARS-CoV-2. https://app.cochat.ai/papers/10.1186/s13073-021-00910-1
The paper
Smith, C. C., Olsen, K. S., Gentry, K. M., Sambade, M., Beck, W., Garness, J., Entwistle, S., Willis, C., Vensko, S., Woods, A., Fini, M., Carpenter, B., Routh, E., Kodysh, J., O’Donnell, T., Haber, C., Heiss, K., Stadler, V., Garrison, E., . . . Rubinsteyn, A. (2021). Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Medicine. https://doi.org/10.1186/s13073-021-00910-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.